Extract

The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and safety.

Inclusion criteria

• Breast Neoplasms

Country

• Belgium
• Canada
• France
• Spain
• United States

Links

• nct
• ictrp